U.S. markets open in 7 hours 51 minutes

Itamar Medical Ltd. (ITMR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.63-1.07 (-4.71%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close22.70
Open22.15
Bid0.00 x 900
Ask0.00 x 800
Day's Range21.43 - 22.15
52 Week Range7.66 - 29.00
Volume3,192
Avg. Volume22,890
Market Cap303.733M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    The German Sleep Society (DGSM) Recognizes PAT™ based Technology in its New Sleep-Related Breathing Disorders Guidelines, Further Benefitting Itamar Medical’s Approach to Sleep Apnea Diagnosis

    Updated guidelines represent a significant milestone in the adoption of Itamar’s Peripheral Arterial Tonometry (PAT) based Home Sleep Apnea Testing (HSAT) in Europe, following adoption in the UK, Holland, and SwedenCAESAREA, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, is pleased to report that The German Sleep Society (DGSM) has released an update to its clinical guidelines for Sleep-Related Breathing Disorders (SRBD) recognizing Peripheral Arterial Tonometry (PAT™) technology as an equivalent alternative to polygraphy-based Home Sleep Apnea Testing (HSAT) systems. The new guidelines were published in Somnologie Magazine on September 9th, 2020. These guidelines set the specifications for accepted technologies and practices to be used in the diagnosis and treatment of SRBD, marking another major achievement in the recognition and adoption of PAT™ technology and PAT-based HSAT systems in Europe. Accreditation by the foremost medical society clinical guidelines, in any market, serves as a fundamental first step in the pathway towards full reimbursement. As such, these updated guidelines may assist in paving the way for the reimbursement of the company’s WatchPAT™ devices in Germany.“We are very pleased to see the recognition of PAT™ technology by the German Sleep Society,” said Eilon Livne, Vice President of Sales and Channels Development EMEA at Itamar Medical. “This is an important landmark as we are committed to removing obstacles in sleep medicine markets worldwide and specifically expanding our reach within the European market. We are excited to begin delivering a comprehensive solution to aid the diagnosis and treatment of sleep apnea patients in Germany and continue filling the substantial gap in the current clinical pathway which leaves the vast majority of Sleep Apnea patients undiagnosed.”Sleep apnea, which affects approximately 1 Billion people worldwide, is a sleep disorder in which breathing repeatedly stops and starts, and is also often associated with other serious health problems, especially cardiovascular disease. Itamar Medical’s PAT™ technology, based on a physiological signal acquired non-invasively from the finger, allows for the simple and accurate diagnosis of this disorder, supporting the company’s efforts to provide an easy access solution to address the estimated 80% undiagnosed Sleep Apnea patient population.To date, PAT™ is the only alternative technology to airflow-based systems, that is accredited and endorsed by U.S, Dutch, UK, and Swedish sleep-related clinical guidelines.“The PAT™ technology provides sleep physicians with unprecedented access to information regarding sleep and sleep disturbance in comparison to standard outpatient recording,” said Prof. Dr. med. Boris A. Stuck, Professor and chair of the Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Germany. “In this context, sleep duration, sleep architecture and sympathetic arousals are of particular interest. Moreover, the technology is easy to handle for both physician and patient.”About WatchPAT™ WatchPAT™, the FDA-approved flagship product developed by Itamar Medical, is used for diagnosing Sleep Apnea in the home environment. The WatchPAT is an easy-to-use patient-led alternative with unique abilities to interpret test results automatically, as well as produce a full sleep report. It provides a variety of respiratory indices, distinguishes between sleep and wakefulness, and provides a complete sleep architecture that includes the analysis of sleep stages such as light sleep, deep sleep and REM sleep. The WatchPAT also records snoring volume and body position information throughout the night. The FDA-cleared Central PLUS Module also enables specific identification of Central Sleep Apnea (CSA).About Itamar Medical Ltd.Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss obtaining reimbursement for our products, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical's control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by us in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including our latest Annual Report on Form 20-F which is on file with the SEC and the ISA. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.Itamar Medical Company Contact Itamar Medical Ltd. Shy Basson Chief Financial Officer Phone: +972-4-617-7700 bshy@itamar-medical.comItamar Medical Investor Relations Contact (U.S.) Leigh Salvo or Caroline Paul Gilmartin Group Phone: +1-415-937-5412 investors@itamar-medical.com

  • GlobeNewswire

    Itamar Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020

    CAESAREA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today announced that management will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference. Itamar’s management is scheduled to present on Wednesday, September 16, 2020 at 9:00 a.m. ET/6:00 a.m. PT. Interested parties may access a live and archived webcast of the presentation on the investor section of the Company’s website at: www.itamar-medical.com.About Itamar Medical Ltd. Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPATTM, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.Company Contact Itamar Medical Ltd. Shy Basson Chief Financial Officer Phone: +972-4-617-7700 bshy@itamar-medical.comItamar Medical Investor Relations Contact (U.S.) Leigh Salvo or Caroline Paul Gilmartin Group Phone: +1-415-937-5412 investors@itamar-medical.com

  • GlobeNewswire

    Prior Authorization Requirement for Itamar’s WatchPAT™ Home Sleep Apnea Test Removed for all Independence Blue Cross Members

    CAESAREA, Israel, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical solutions to aid in the diagnosis of respiratory sleep disorders, today announced that effective July 2020, Independence Blue Cross (IBC) has removed their prior authorization requirement for home sleep apnea tests (HSAT) following an extensive dialog that included presentation of evidence. All membership approaching five million members across 27 states has been impacted within the Family of Companies, which includes Independence Blue Cross, AmeriHealth New Jersey, Independence Administrators, and AmeriHealth Administrators.While Medicare does not require prior authorization for home sleep studies, most commercial health plans still require it for their members, practically reducing materially the economic incentive to conduct HSATs. With this update, nearly all IBC members will benefit from the option to take a sleep apnea test at home with no pre-authorization burden.It is estimated that 54 - 60 million people in the U.S suffer from sleep apnea, with roughly 80% of cases going undiagnosed and even more untreated. Sleep apnea is a sleep disorder in which breathing repeatedly stops and starts. Sleep apnea is also often associated with other serious health problems, especially cardiovascular disease.“We are excited that undiagnosed patients of IBC with suspected Obstructive Sleep Apnea can now more easily access the tests they need to confirm their diagnosis and manage their condition,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical. “Sleep apnea is not only a serious ailment; it is also often an indicator  and independent risk factor of other serious health disorders. We are committed to continue to lead the journey of reducing the barriers sleep apnea patients face as we develop a more efficient alternative to the traditional care pathway so that people can be diagnosed for sleep apnea safely, quickly and efficiently from the comfort of their own bed. I want to thank the Baker Tilly health economic team in supporting our market access roadmap and this first win.”About Itamar Medical Ltd. Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss reducing the barriers sleep apnea patients face to undergoing a sleep apnea test, we are using forward-looking statements.  Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical's control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by Itamar Medical in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including the Company’s latest Form 20-F which is on file with the SEC (accessible at www.sec.gov) and the ISA. Except as otherwise required by law, Itamar Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.The contents of any website or hyperlinks mentioned in this press release are for informational purposes only and the contents thereof are not part of this press release nor is it incorporated herein by reference. Company Contact Itamar Medical Ltd. Shy Basson Chief Financial Officer Phone: +972-4-617-7700 bshy@itamar-medical.comItamar Medical Investor Relations Contact (U.S.) Leigh Salvo or Caroline Paul Gilmartin Group Phone: +1-415-937-5412 investors@itamar-medical.com